Antineoplastic drugs have been shown to exert direct eŠects on the gut and induce the release of serotonin from the enterochroma‹n cells of small intestinal mucosa. It is thought that released serotonin stimulates vagal aŠerentˆbers through 5-HT 3 receptors located in the vagal aŠerent terminals in the gastrointestinal tract and initiates sensory signals to the area postrema and the emetic center, thereby initiating nausea and vomiting. A 5-HT 3 antagonist competitively inhibits serotonin at its speciˆc binding sites, 5-HT 3 receptors, and thereby elicits an antiemetic eŠect. Therefore 5-HT 3 receptor occupancy of serotonin may be an appropriate indicator of the antiemetic activity of 5-HT 3 antagonists. We analyzed 5-HT 3 receptor occupancy of serotonin by integrating pharmacokinetic and receptor-binding kinetic parameters based on the receptor occupancy theory to compare the strength of the antiemetic eŠects of three dosage regimens of azasetron hydrochloride. The inhibitory eŠects on the binding of serotonin to 5-HT 3 receptor of regimen 2 (an intravenous bolus injection of 5 mg of azasetron hydrochloride before and 8 h after chemotherapy) and regimen 3 (an intravenous bolus injection of 2.5 mg followed by 7.5 mg continuous intravenous infusion for 24 h) were longer-lasting than those of regimen 1 (an intravenous bolus injection of 10 mg before the start of chemotherapy). Furthermore, a positive relationship was found between the time of inhibitory eŠects on the binding of serotonin to 5-HT 3 receptor and antiemetic eŠects of azasetron hydrochloride. From these results, dosage regimens 2 and 3 were considered to be more eŠective in the long term than regimen 1 in prophylaxis of nausea and vomiting induced by cisplatin. 
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